Clinical results of a GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

Eli Lilly stock soared Thursday after the pharmaceutical giant said its new weight-loss pill had cleared a late-stage ...

The positive data gives Eli Lilly the green light to file the drug with the FDA by the end of the year for a weight-loss indication.

One of the foremost hurdles encountered in the pursuit of weight loss is the apprehension of physical exhaustion and the ...

On today's Market Minute, Madison Mills takes a closer look at the top stories on Wall Street. UnitedHealth Group (UNH) stock ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Explore medication options for kidney disease and potential side effects. Learn the best treatment options to slow ...